Renoprotection in Diabetes: Bridging the Gap Between Promising Mechanisms and Clinical Inconsistency

With the advent of new pharmacological options for the treatment of diabetes, a growing number of agents with notable pleiotropic properties have emerged. Beyond their primary glucose-lowering mechanisms, these drugs have demonstrated a broad spectrum of secondary actions, including cardiovascular, metabolic, and renal effects. In particular, their potential renoprotective capacity has generated considerable interest in recent years as diabetic kidney disease remains one of the most prevalent and clinically challenging complications associated with diabetes.A substantial body of evidence has suggested that these agents may contribute to the preservation of kidney structure and function through several mechanisms. Some clinical and experimental studies report that their use is associated with a delay in the progression of chronic kidney disease, characterized by attenuation of interstitial fibrosis, reduction of glomerular inflammation, improvements in oxidative stress, and, most importantly, a slower decline in the glomerular filtration rate (GFR). These findings propose that pleiotropic drugs may exert direct protective effects on renal cells, modulate hemodynamic pathways, or mitigate metabolic stressors that accelerate nephron loss.However, despite these promising results, the literature remains controversial. Other investigations have failed to demonstrate significant improvements in renal endpoints, raising questions about the consistency and generalizability of the observed benefits. Differences in study design, follow-up duration, baseline renal function, and the presence of comorbidities may partially explain these discrepancies. Additionally, an ethnic or population effect has been proposed, given that genetic, environmental, and socioeconomic factors can markedly influence both drug response and disease progression.This Research Topic is therefore dedicated to exploring chronic kidney disease with particular emphasis on therapeutic agents that exhibit pleiotropic actions. The goal is to highlight current evidence, ongoing debate, and emerging hypotheses regarding the mechanisms through which these drugs may confer renoprotection. These protective actions may manifest as delayed fibrotic remodeling, slower GFR decline, antioxidant activity, anti-inflammatory effects, or modulation of pathways involved in cellular stress. Understanding these multifaceted effects is essential for advancing therapeutic strategies and improving renal outcomes in patients with chronic kidney disease. Topic editors: Katy Sanchez-Pozos, Rafael Valdez-Ortiz, Roberto Lugo, Victoria Ramírez, Swati Kaushik Source: https://www.frontiersin.org/research-topics/77542/renoprotection-in-diabetes-bridging-the-gap-between-promising-mechanisms-and-clinical-inconsistency